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10 The Journal of Thoracic and Cardiobjectives: In chronic thromboembolic pulmonary hypertension, objective data to
ssess the functional outcome after pulmonary endarterectomy are lacking. We
tudied the 6-minute walk distance in relation to the clinical and hemodynamic
everity of disease, and assessed the effect of pulmonary endarterectomy on the
-minute walk distance.
ethods: A total of 50 consecutive patients with chronic thromboembolic pulmo-
ary hypertension were studied. Subsequently, pulmonary endarterectomy was
erformed in 42 patients, 35 of whom underwent a 6-minute walk distance 1 year
fter surgery.
esults: The mean  standard error of the mean 6-minute walk distance was 391 
9 m. The 6-minute walk distance decreased in proportion to New York Heart
ssociation functional class and correlated (all P  .0001) with mean pulmonary
rtery pressure (r  0.62), cardiac output (r  0.76), total pulmonary resistance
r  0.75), mixed venous oxygen saturation (r  0.77), and brain natriuretic
eptide (r  0.65). One year after pulmonary endarterectomy, the 6-minute walk
istance increased from 417  19 m to 517  16 m (P  .0001). The change from
aseline in 6-minute walk distance correlated with the changes after 1 year in New
ork Heart Association functional class (P .01) and brain natriuretic peptide (r
.57, P  .002), and with the observed hemodynamic changes directly after
ulmonary endarterectomy (change in mean pulmonary artery pressure: r  0.52;
hange in cardiac output: r  0.70; change in total pulmonary resistance r  0.70;
ll P  .001). In patients with residual pulmonary hypertension after pulmonary
ndarterectomy, the 6-minute walk distance was significantly lower than in hemo-
ynamically normalized patients. However, the absolute increase in the 6-minute
alk distance was higher in patients with residual pulmonary hypertension (137 
6 m and 82  20 m, respectively; P  .03).
onclusions: The 6-minute walk distance was demonstrated to reflect the clinical
nd hemodynamic severity of disease in patients with chronic thromboembolic
ulmonary hypertension. One year after pulmonary endarterectomy, the 6-minute
alk distance had increased significantly, and the change in the 6-minute walk
istance correlated with the observed clinical and hemodynamic improvement.
 
he 6-minute walk test (6-MWT) is a reproducible, safe, and simple
submaximal exercise test that can be used to evaluate exercise limitation
in patients with cardiac and pulmonary diseases.1 The 6-minute walk
istance (6-MWD) was shown to correlate with peak oxygen consumption (peak
O2) in patients with advanced heart failure2,3 or idiopathic pulmonary arterial
ypertension (iPAH).4 In iPAH, the 6-MWD was also correlated with hemodynamic
everity of disease and independently associated with mortality.4 Moreover, in
vascular Surgery ● February 2007
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PPAH, the 6-MWT was repeatedly used to assess changes in
unctional capacity in studies on the effectiveness of med-
cal treatment.5-7
Chronic thromboembolic pulmonary hypertension (CTEPH)
esults from incomplete resolution of the vascular obstruc-
ion associated with pulmonary embolism.8 CTEPH is a
ife-threatening9 but potentially correctable form of pulmo-
ary hypertension by means of pulmonary endarterectomy
PEA).8 After surgery, most patients experience a signifi-
ant hemodynamic improvement, which is associated with
mprovements in reported New York Heart Association
NYHA) functional class and long-term survival.10 How-
ver, as the American College of Chest Physicians Evidence-
ased Clinical Practice Guidelines for Surgical Treatments
or Pulmonary Arterial Hypertension stated, objective data
eg, the 6-MWD) to assess the postoperative functional
tatus are still lacking in patients with CTEPH after PEA.11
n fact, data on the correlation of the 6-MWD with param-
ters reflecting clinical and hemodynamic severity of dis-
ase in CTEPH were not studied before.
Therefore, we studied the 6-MWD in relation to the
linical and hemodynamic severity of disease in patients
ith CTEPH. Moreover, we assessed the level of improve-
ent of the 6-MWD 1 year after PEA and studied its
elation to the postoperative clinical and hemodynamic
utcome.
ethods
tudy Subjects
ifty consecutive patients (29 females, mean age 53  2 years,
ange 16–85 years) with a diagnosis of CTEPH, who were re-
erred to the Academic Medical Center of the University of Am-
terdam between July 2003 and July 2005, were studied. The
iagnosis of CTEPH was established on the basis of previously
eported procedures.12 Diagnosis and cardiopulmonary hemody-
amics were determined by pulmonary angiography and right-
ided heart catheterization. Pulmonary hypertension was defined as
ean pulmonary artery pressure (mPAP) greater than 25 mm Hg
t rest (n  42) or greater than 30 mm Hg during a standardized
xercise test on a cycle ergometer (n  8).13 In all patients, normal
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CO  cardiac output
CTEPH chronic thromboembolic pulmonary
hypertension
iPAH  idiopathic pulmonary arterial hypertension
mPAP mean pulmonary artery pressure
PEA  pulmonary endarterectomy
SvO2  venous oxygen saturation
TPR  total pulmonary resistance
WSR Wilcoxon signed-rankseft ventricular function was documented by echocardiography. In l
The Journal of Thoracicddition, coronary angiography was routinely performed in all
atients aged more than 40 years. Postoperative hemodynamics
ere determined on the first or second day after PEA, before
emoval of the Swan-Ganz catheter. All patients received oral
nticoagulation therapy for at least 3 months before referral to our
ospital. All investigations were approved by the local institutional
eview board.
ix-minute Walk Test
he 6-MWT was routinely performed in all patients according
o the guidelines of the American Thoracic Society.1 At least 1
ractice walk test was performed. All tests were supervised by
respiratory function technologist encouraging subjects with
tandard phrases as stated in the American Thoracic Society
rotocol. Patients were instructed to walk at their own pace
long a 40-m corridor and to cover as much ground as possible
n 6 minutes.
For each patient, the predicted 6-MWD was estimated by use of
he regression equation described by Enright and Sherill.14
ew York Heart Association
ach patient was functionally classified according to the NYHA
lassification of the World Health Organization before enrollment
n the study and, if applicable, 1 year after PEA.15
lood Sampling and Assay
lood samples were analyzed at baseline (n  47) and 1 year
fter PEA (n  33) for brain natriuretic peptide (BNP) as a
arker of right ventricular function.16 Samples were obtained
rom the brachial vein for plasma (ethylenediamine-tetra-acetic
cid), centrifuged at 3000 rpm for 10 min at 4°C, and subse-
uently stored at 80°C until analysis. The patients were in a
orizontal position for at least 15 minutes before the blood
amples were obtained. BNP levels were determined by an
mmunoradiometric assay (Shionoria, Osaka, Japan), as previ-
usly described.17
tatistical Analysis
ll data are expressed as mean  standard error of the mean. All
nalyses were performed using the statistical package SPSS 11.5
SPSS Inc, Chicago, Ill). The Jonckheere–Terpstra test was used to
nalyze the trend between the 6-MWD (continuous variable) and
YHA functional class (discontinuous variable).18 The differences
etween groups were tested with a parametric 1-way analysis of
ariance. In case of an overall statistical difference, the differences
etween 2 groups were further analyzed with the Student t test
ith Bonferroni’s correction for multiple comparisons. Pearson’s
orrelation test was used to assess correlations between the
-MWD and the hemodynamic parameters, and was tested for
-sided significance. Stepwise linear regression analysis was per-
ormed to calculate the predictive value of the individual param-
ters in relation to the 6-MWD. The Wilcoxon signed–ranks
WSR) test was used to analyze the effect of PEA on the 6-MWD.
pearman’s rank correlation test was used to assess correlations
etween the change on PEA in the 6-MWD and the observed
hanges in the hemodynamic parameters, and was tested for
-sided significance. The Mann-Whitney U test was used to ana-
yze the difference between patients with normalized pulmonary
and Cardiovascular Surgery ● Volume 133, Number 2 511
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CSPemodynamics (mPAP  25 mm Hg) and patients with residual
ulmonary hypertension (mPAP  25 mm Hg).
esults
ll 50 patients underwent a full preoperative evaluation.
ubsequently, 42 patients underwent a PEA procedure, that
s, 37 patients with pulmonary hypertension at rest and 5
atients with exercise-induced pulmonary hypertension.
he latter patients were selected for surgery on the basis of
reviously described criteria.8,19 They all had disabling
mpairment of exercise tolerance and angiographic evidence
or proximal chronic thromboembolic occlusion of at least 2
obes. Five patients were considered to have distal, inoper-
ble CTEPH. In 3 of the 8 patients with exercise-induced
ulmonary hypertension, a PEA was postponed.
The characteristics of the patients are summarized in
able 1. Most patients with pulmonary arterial hypertension
t rest (n  42) had moderate to severe pulmonary hyper-
ension, with a median mPAP of 48 mm Hg (range 26–75
m Hg) and a median total pulmonary resistance (TPR) of
76 dynes/sec/cm5 (range 301–2064 dynes/sec/cm5).
symptomatic coronary artery disease was present in 2
atients with a significant stenosis in the left anterior de-
cending coronary artery and the right coronary artery,
ABLE 1. Baseline characteristics
mPAP > 25 mm Hg mPAP < 25 mm Hg
ubjects, n 42 8
emographics
Age, y 54 2 52  5
Female/male, n 23/19 6/2
Weight, kg 82 2 82  7
Height, cm 173 2 169  7
BSA, m2 2.03 0.05 1.93 0.07
YHA, n
II 1 8
III 35
IV 6
esting hemodynamics
mPAP, mm Hg 48 2 22  1
CO, L/min1 4.1  0.2 6.5  0.5
TPR, dynes/sec/cm5 1038 71 277 23
mRAP, mm Hg 11 1 6  1
PCPW, mm Hg 13 1 (n  35) 9  1 (n  7)
SvO2, % 57  2 (n  38) 72 1
eurohormones
BNP, pg/L 51 9 (n  40) 3  1 (n  7)
NP, Brain natriuretic peptide; BSA, body surface area; CO, cardiac
utput; NYHA, New York Heart Association; mPAP, mean pulmonary artery
ressure; mRAP, mean right atrial pressure; PCWP, pulmonary capillary
edge pressure; SvO2, venous oxygen saturation; TPR, total pulmonary
esistance. All values are expressed as mean  standard error of the
ean.espectively. 6
12 The Journal of Thoracic and Cardiovascular Surgery ● Febrorrelates of 6-Minute Walk Distance in Patients
ith Chronic Thromboembolic Pulmonary
ypertension
he mean  standard error of the mean of the 6-MWD was
91  19 m. The 6-MWD decreased significantly in pro-
ortion to the severity of NYHA functional class (Figure 1),
nd a statistically significant negative trend was demon-
trated (P  .0001; Jonckheere–Terpstra test). The 6-MWD
orrelated significantly with mPAP, cardiac output (CO),
PR, and mixed venous oxygen saturation (SvO2) (Figure
, A–D). The mean right atrial pressure (r  0.52, P 
0001; Pearson’s test) and levels of plasma BNP (n  47;
 0.53, P  .0001; Pearson’s test) showed significant
orrelations with the 6-MWD. In contrast, pulmonary cap-
llary wedge pressure (n  42) did not correlate with the
-MWD (P  .8).
After exclusion of the 8 patients with exercise-induced
ulmonary arterial hypertension, significant correlations be-
ween the 6-MWD and the hemodynamic parameters were
emonstrated (Pearson’s test): mPAP: r0.46, P .005;
O: r  0.65, TPR: r  0.65, SvO2: r  0.69 (all P 
0001); mean right atrial pressure r  0.44 (P  .005);
NP r  0.46 (P  .005).
By multivariate linear regression analysis of all individual
arameters that correlated significantly with the 6-MWD, only
vO2 and CO were shown to be independently associated with
he 6-MWD (model: r2  0.63, P  .0001; SvO2:   0.49,
 .001; CO:   0.36, P  .02).
ffect of Pulmonary Endarterectomy
n 35 of the 42 patients in whom a PEA was performed, a
igure 1. The 6-MWD in relation to NYHA functional class in
atients with CTEPH (Student t test with Bonferroni’s correction
or multiple comparisons). NYHA, New York Heart Association;
-MWD, 6-minute walk distance.-MWT was obtained 1 year postoperatively. Four patients
uary 2007
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Pied postoperatively, 2 of progressive right heart failure
aused by persistent pulmonary hypertension and 2 of post-
perative massive alveolar hemorrhage. In addition, 3 pa-
ients were excluded from the analysis after 1 year because
hey were already treated medically for symptomatic
NYHA III/IV) residual pulmonary hypertension.
In the 35 patients, PEA was associated with significant
emodynamic improvement (WSR test): mPAP decreased
rom 44  3 mm Hg to 25  1 mm Hg (P  .0001); CO
ncreased from 4.6  0.2 L/min1 to 5.0  0.2 L/min1
P  .5); and TPR decreased from 878  88 dynes/sec/
m5 to 444  33 dynes/sec/cm5 (P  .0001).
Directly after PEA, 12 patients had (by definition) resid-
al pulmonary hypertension (mPAP  25 mm Hg; range
6–48 mm Hg), 4 of whom had an mPAP greater than 30
m Hg. Hemodynamically, the patients with residual pul-
onary hypertension represented the more severely affected
atients; preoperative mPAP was significantly higher in
Figure 2. Correlations between the 6-MWD and the
r  0.62; P < .0001. B, CO; Pearson r  0.76; P < .00
n 46; Pearson r 0.77; P< .0001. mPAP, Mean pulmo
total pulmonary resistance; CO, cardiac output; SvO2,atients with residual pulmonary hypertension compared a
The Journal of Thoracicith patients with normalized pulmonary hemodynamics
55 9 mm Hg vs 36 10 mm Hg, P .0001; WSR test).
One year after PEA, NYHA functional class had im-
roved in all but 2 patients (Figure 3), and the 6-MWD had
ncreased from 417  19 m to 517  16 m (P  .0001;
SR test). The change in NYHA functional class correlated
ignificantly with the change in the 6-MWD (P  .02;
onckheere Terpstra test). In addition, the observed change
) in the 6-MWD correlated with the change from baseline
year after PEA in plasma BNP levels (BNP: r  0.57,
 .002; Spearman’s rank correlation test). In addition, the
hange from baseline in the 6-MWD 1 year after PEA
orrelated significantly with the change from baseline ob-
erved in the hemodynamic parameters directly after PEA
mPAP: r 0.52; CO: r 0.70; TPR r 0.70; all P
001; Spearman’s rank correlation test).
The 6-MWD in patients with and without residual pul-
onary hypertension differed significantly both before and
onary hemodynamic parameters. A, mPAP; Pearson
, TPR; Pearson r  0.75; P < .0001. D, Mixed SvO2;
artery pressure; 6-MWD, 6-minute walk distance; TPR,
s oxygen saturation.pulm
01. C
nary
venoufter PEA (Figure 4, A). In patients with residual pulmonary
and Cardiovascular Surgery ● Volume 133, Number 2 513
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CSPypertension, the 6-MWD, expressed as percentage of pre-
icted, was significantly lower than in hemodynamically
ormalized patients. The absolute increase in the 6-MWD,
owever, was significantly higher in patients with residual
ulmonary hypertension (mPAP 25 mm Hg: 137 26 m,
nd mPAP 25 mm Hg: 82 20 m, respectively; P .03;
ann-Whitney U test).
One year after PEA, the 6-MWD expressed as the percent-
ge of predicted had increased from 69% 4% to 87% 3%
P  .0001; WSR test). The 6-MWD 1 year after PEA par-
icularly tended to normalize in the patients with normalized
ulmonary hemodynamics after PEA (Figure 4, B).
iscussion
n the present study, we demonstrated that the 6-MWD
orrelated with parameters reflecting clinical and hemody-
amic severity of disease in CTEPH. PEA resulted in a
ignificant increase in the 6-MWD 1 year after surgery.
oreover, the change in the 6-MWD correlated with the
bserved clinical and hemodynamic improvement.
Previously, in patients with iPAH, the 6-MWD was
hown to correlate significantly with hemodynamic severity
f disease.4 Compared with the data reported in these pa-
ients, however, the correlations observed between the
-MWD and pulmonary hemodynamics in the present study
eem more robust. In fact, the mean PAP did not correlate
igure 3. NYHA functional class in individual patients (n  35)
efore and 1 year after PEA (WSR test). NYHA, New York Heart
ssociation; PEA, pulmonary endarterectomy.ith the 6-MWD in patients with iPAH. This difference s
14 The Journal of Thoracic and Cardiovascular Surgery ● Febray be explained, at least in part, by the inclusion of
atients with exercise-induced pulmonary hypertension in
he current study. By inclusion of these patients, we were
ble to study the whole spectrum of disease severity. Inclu-
ion of these patients in the correlations between the
-MWD and the hemodynamic parameters at rest, however,
ay have affected the statistical significance of these cor-
elations. Exclusion of these patients from the analyses,
owever, only modestly affected the statistical significance
f the observed correlations.
In the present study, parameters reflecting (impairment
f) cardiac function (ie, CO, SvO2, and plasma BNP levels)
igure 4. The 6-MWD before and 1 year after PEA in 35 patients in
elation to postoperative hemodynamic outcome (Mann-Whitney U
est). Patients with residual pulmonary hypertension (open bars)
mPAP > 25 mm Hg; n  12); patients with normalized pulmonary
emodynamics (solid bars) (n  23). A, 6-MWD expressed as the
bsolute distance walked (m). B, 6-MWD expressed as percentage
f predicted values. PEA, Pulmonary endarterectomy; 6-MWD,
-minute walk distance.trongly correlated with the distance walked in the 6-MWT,
uary 2007
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Pven without apparent loss of correlation in the most se-
erely affected patients. By multivariate linear regression
nalysis, SvO2 and CO were demonstrated to be indepen-
ently associated with the 6-MWD. The current data in
atients with CTEPH are consistent with previous observa-
ions in patients with iPAH, that is, the 6-MWD is in major
art related to the parameters reflecting the (right-sided)
eart function.4,20
In the patients who performed a 6-MWT 1 year after
EA, a significant improvement of the 6-MWD was ob-
erved. Moreover, the change in the 6-MWD correlated
ith the observed changes in the hemodynamic parameters
irectly after PEA. In fact, the 6-MWD 1 year after PEA
iffered between patients with and without residual pulmo-
ary hypertension. Although pulmonary hemodynamics
ay improve up to 2 years after PEA,21 evidence of residual
ulmonary hypertension directly after PEA seemed to dis-
riminate and was associated with a significantly lower
-MWD 1 year after PEA. Preoperatively, the group with
esidual pulmonary hypertension represented, clinically and
emodynamically, the more severely affected patients. The
bserved improvement in the 6-MWD in the patients with
esidual pulmonary hypertension, however, was even higher
han in the patients with normalized pulmonary hemody-
amics. Thus, although these patients were not fully nor-
alized hemodynamically after PEA, functionally, they
ruly benefited from surgical treatment. Moreover, it should
e emphasized that these patients (who are likely to have
ore distally localized chronic thromboembolic disease)
ay benefit more from PEA in highly experienced centers.
To estimate the extent of normalization of functional
apacity after PEA, we calculated predicted values for the
-MWD according to the regression equation of Enright and
herill.14 One year after a hemodynamically successful
EA, the 6-MWD expressed as the percentage of the pre-
icted value appeared within the normal range. Normaliza-
ion of functional capacity in these patients was consistent
ith the fact that the (more subjective) NYHA functional
lass was I/IV in all patients. Interpretation of this observa-
ion, however, should be done with some care. The algo-
ithm was validated in individuals between 40 and 80 years
f age, whereas, in this series, 9 patients with normalized
ulmonary hemodynamics were aged less than 40 years. By
ssuming that younger people can walk a longer distance
han predicted by the algorithm, this may lead to an apparent
ormalization of the functional capacity expressed as the
ercentage of predicted. This may have a positive effect on
he observed outcome in the entire group. However, because
either the absolute 6-MWD nor the 6-MWD expressed as
he percentage of predicted value differed between both
roups 1 year after PEA, this seems unlikely.
Although the subgroup of patients with CTEPH in
hom a 6-MWT was performed 1 year after PEA repre-
1
The Journal of Thoracicented those who underwent operation consecutively,
ome selection bias may have occurred. Four patients
ied postoperatively, and 3 patients were excluded from
he analysis after 1 year because they were already
reated medically for symptomatic (NYHA III/IV) resid-
al pulmonary hypertension.
onclusions
he 6-MWT is a safe, easy-to-perform, noninvasive, sub-
aximal exercise test that was demonstrated in this study to
eflect the clinical and hemodynamic severity of disease in
atients with CTEPH. One year after PEA, the 6-MWD
ncreased significantly, and the change correlated with the
bserved clinical and hemodynamic improvement. More-
ver, in patients with normalized pulmonary hemodynamics
fter PEA, the 6-MWD, expressed as the percentage of the
redicted value, tended to normalize.
The authors thank Dr Jaring S. van der Zee for his constructive
omments on the article.
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